Medicaid Expansion and Survival Outcomes among Men with Prostate

1

Cancer 2 3 Oluwasegun Akinyemi^{1,2}, Mojisola Fasokun³, Eric Hercules¹, Seun Ikugbayigbe⁴, Eunice 4 Odusanya¹, Nadia Hackett¹, Oluebubechukwu Eze¹, Lerone Ainsworth⁵, Kakra Hughes⁵, Edward 5 Cornwell III⁵ Pamela Coleman⁵ 6 7 ¹Department of Surgery Outcomes Research Center, Howard University College of Medicine, 8 Washington DC, USA 9 ²Department of Health Policy and Management, University of Maryland College Park, MD, USA 10 ³Department of Epidemiology, University of Alabama at Birmingham, AL, USA 11 ⁴Department of Public Health, Eastern Illinois University, Charleston., IL, USA 12 ⁵Department of Surgery, Howard University College of Medicine, Washington DC, USA 13 14 **Short Title:** Medicaid Expansion and Prostate Cancer Survival

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

ABSTRACT INTRODUCTION: Prostate cancer stands as one of the most diagnosed malignancies among men worldwide. With the recent expansion of Medicaid under the Affordable Care Act (ACA), millions more Americans now have health insurance coverage, potentially influencing healthcare access and subsequent outcomes for various illnesses, including prostate cancer. Yet, the direct correlation between Medicaid expansion and cancer-specific survival, particularly for early-stage prostate cancer, remains an area warranting comprehensive exploration. OBJECTIVE: This study aims to determine the impact of the implementation of Medicaid expansion on Survival outcomes among men with prostate cancer. METHODS: We utilized data from the SEER registry to determine the causal impact of the implementation of the ACA on outcomes among men with prostate cancer. The study covered the years 2003-2021, divided into pre-ACA (2003-2009) and post-ACA (2015-2021) periods, with a 1-year washout (2014-2015) since Medicaid expansion was implemented in 2014 in Kentucky. Using a Difference-in-Differences approach, we compared survival among men with prostate cancers from Kentucky to Georgia. We adjusted for patient demographics, income, metropolitan status, disease stage, and treatment modalities. RESULTS: We analyzed a cohort of 68,222 men with prostate cancer during the study period. Of these, 37,810 (55.4%) were diagnosed in the pre-ACA period, with 70.8% from Georgia and 29.2% from Kentucky. The remaining 30,412 (44.6%) were diagnosed in the post-ACA period, with 72.3% from Georgia and 27.7% from Kentucky. Medicaid expansion in Kentucky was associated with a 16.8% reduction in hazard of death (HD), indicating improved overall survival among low-income individuals. This trend was consistent across different racial/ethnic groups. Specifically, Non-Hispanic white men experienced a 16.2% reduction (DID = -0.162, 95% CI: -

38 0.315 to -0.008), Non-Hispanic Black men had a 17.9% reduction (DID = -0.179, 95% CI: -

39 0.348 to -0.009), and Hispanic men saw a 15.9% reduction (DID = -0.159, 95% CI: -0.313 to -

40 0.005) in HD among low-income individuals.

42

43

44

41 CONCLUSION: Medicaid Expansion was associated with a substantive improvement in overall

survival among men with prostate cancers in Kentucky compared to non-expansion Georgia.

INTRODUCTION

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

Outside of skin cancer, prostate cancer is the most common cancer in men in the United States (U.S.) [1], with approximately 299,010 new cases of prostate cancer expected in 2024, along with about 35,250 deaths from the disease [2]. Since 2014, the incidence rate has sharply increased 3% per year overall and 5% per year for advanced-stage prostate cancer [2]. For men diagnosed with prostate cancer, the treatment can range from observation, curative surgery (prostatectomy), and targeted radiation therapy [3], however, what is not often discussed are the factors that determine the treatment of choice [3,4]. Financial toxicity is a term that is used to describe the financial consequences and the potential stress incurred by a disease diagnosis and treatment [5]. In 2020 alone, there was an estimated \$22.3 billion spent on prostate cancer care, with the majority of that being made up by direct medical expenses [6]. However, the economic impact goes far beyond medical bills. Prostate cancer leads to very significant lost earnings as a result of premature mortality and the inability of patients to work during their treatment and recovery process [7]. Prostate cancer is a very complex disease whose pathogenesis involves both genetic and environmental factors and is mainly driven by alterations in androgen signaling [8]. There are a multitude of risk factors that contribute to the development of prostate cancer, including age, family history, and race [9]. African American men are at a higher risk of developing prostate cancer and usually tend to present with a more advanced disease at diagnosis compared to their counterparts [10]. It has also been shown that social determinants of health (SDOH) have a significant impact on prostate cancer outcomes(11). Factors such as socioeconomic status, access to healthcare, and living conditions not only influence the state at which prostate cancer is

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

diagnosed, but also overall survival rates [12]. Prior data suggests that incidence rates are associated with socioeconomic status [10]. Additionally, lower socioeconomic status is associated with poorer survival rates [10]. In order to reduce disparities in prostate cancer care and improve survival, it is crucial to address the SDOH that may be impacting the outcomes of disease. The goal of Medicaid, initially enacted in 1965, was to allow States to receive federal funding to provide health insurance to persons with limited income [13]. This legislation was later expanded and termed The Affordable Care Act (ACA), passed in 2010 and fully implemented in 2014 [14]. This legislation addressed Americans without health insurance facing systemic health inequalities [14]. This act is the most significant expansion of coverage in the US healthcare system following the creation of Medicare and Medicaid in 1965 [15]. Before the ACA, there were limitations to Medicaid eligibility on the state level, which covered only the poorest in specific categories (i.e., disabled people, pregnant women, and children) [15]. In contrast, with the ACA, citizens with income at or below 138% of the federal poverty line qualify for aid [14]. Due to ACA, the number of uninsured individuals declined significantly from 2013 to 2022, from approximately 45.2 million to 26.4 million [5]. The overall implementation of the Affordable Care Act during 2013-2022 has led to an overall 45% increase in Americans with health insurance coverage [16]. When looking specifically at the effect of the ACA on patients newly diagnosed with breast, colorectal, and lung cancer from 2012 to 2015 there has been an increase in earlier stage of diagnosis and lower hazard of mortality among patients [17]. A study done written by Eugia et al assessed the effect of Medicaid expansion in states with coverage in patients with bladder, colorectal, esophageal, lung, bladder and gastric cancers and found that there was a increase in

number patients who had access to healthcare and noted a positive effect on access and utilization of oncologic care [18]. We understand the significance of the implementation of the affordable care act on the improved access of care utilization, however direct correlation between Medicaid expansion and cancer-specific survival, particularly for early-stage prostate cancer, remains an area warranting comprehensive exploration. This study aims to determine the impact of the implementation of the Affordable Care Act on cancer-specific survival among men with early-stage prostate malignancies.

METHODOLOGY

Data Source and Study Population

This retrospective cohort study utilized data from the Surveillance, Epidemiology, and End Results (SEER) database, focusing on men diagnosed with prostate cancer between 2000 and 2021[19]. SEER collects cancer incidence and survival data from population-based cancer registries covering approximately 48% of the U.S. population as of 2021 [20]. The study utilized the "Incidence - SEER 18 Registries, Nov 2021 Sub (2000–2021)" database [19]. Inclusion criteria included: (1) men diagnosed with prostate malignancies identified using International Classification of Diseases for Oncology, 3rd edition (ICD-O-3) codes; (2) patients with complete clinicopathological information and survival data; (3) age at diagnosis between 18 - 64yrs; and (4) patients actively followed up. Exclusion criteria were: (1) patients diagnosed through autopsy or death certificate only, or with clinical diagnoses only; (2) patients with missing data on race/ethnicity, household median income, state identification, or years of follow-up. This study involved publicly available data and did not include any identifiable patient information, so

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

institutional review board approval was not required. Informed consent was also not necessary due to the retrospective nature of the study. Georgia vs. Kentucky Georgia (control state) and Kentucky (treated state) were selected for the study due to their contrasting approaches to healthcare policy, specifically regarding the implementation of the Affordable Care Act (ACA). Kentucky expanded Medicaid under the ACA in 2014, leading to a significant increase in Medicaid/CHIP enrollment and a reduction in the uninsured rate. In contrast, Georgia did not expand Medicaid, resulting in higher uninsured rates and more restrictive access to healthcare services. The differences in healthcare policy between the two states provide a unique opportunity to assess the impact of the ACA on prostate cancer outcomes, particularly cancer-specific survival and overall survival. **Primary Outcome of Interest** The primary outcomes of interest were cancer-specific survival (CSS) and overall survival (OS). CSS was defined as the time from diagnosis to death due to prostate cancer, while OS referred to the time from diagnosis to death from any cause. Both outcomes were assessed over two periods: pre-ACA (2003-2009) and post-ACA (2015-2021). **Independent Variables of Interest** The primary independent variables were the implementation of the ACA and Medicaid expansion, categorized into two time periods: pre-ACA (2003-2009) and post-ACA (2015-2021) with a 1-year washout period of January 2014- December 2014 to allow for the policy to become fully operational. Kentucky's Medicaid expansion served as the treatment, while Georgia, which did not expand Medicaid, served as the control. The interaction between state and time period

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

(State X ACA) was used to evaluate the differential impact of the ACA on prostate cancer outcomes between the two states. **Covariates** Covariates included demographic factors such as age at diagnosis (continuous variable), race/ethnicity (categorized as Non-Hispanic White people, Non-Hispanic Black people, Hispanic people, Non-Hispanic Asian/Pacific Islander people, and Native American people), and marital status (categorized as married, widowed, divorced, separated, or unknown). Socioeconomic status was assessed using household median income (>\$64,000 and ≤\$64,000). Tumor characteristics, including stage at diagnosis (localized, regional, distant), and treatment modalities (prostatectomy, chemotherapy, radiation) were also included as covariates. Theoretical Model: Andersen Behavioral Model This study uses the Andersen Behavioral Model of Health Services [21, 22] Use to explore the impact of the ACA and Medicaid expansion on prostate cancer mortality, comparing Kentucky (which implemented Medicaid expansion in 2014) and Georgia (which has not). The model categorizes factors into predisposing, enabling, and need factors: Predisposing Factors: These include demographics such as age (18-45, 45-64 years), race/ethnicity (White, Black, Hispanic, etc.), and marital status (single, married, etc.), which influence healthcare-seeking behavior. Enabling Factors: These are resources that facilitate access to care, including income (<64K, >64K), metropolitan status (rural, small, medium, large metropolitan), and the state of residence (Louisiana vs. Georgia), reflecting the impact of Medicaid expansion.

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

Need Factors: These include clinical variables such as cancer grade (Stage I, Stage II, Stage III) and Stage IV), and the receipt of treatments like surgery, chemotherapy, and radiotherapy, all of which influence prostate cancer outcomes. Difference-in-Differences (DID) Specification The present study used a DID model to estimate the impact of Medicaid expansion on prostate cancer outcomes; overall survival, overall deaths, and disease stage at presentation by comparing Kentucky (treatment group, which implemented Medicaid expansion) to Georgia (control group, which did not) during the pre-ACA and post-ACA periods. The variable ACA was set to 1 for the post-Medicaid expansion period (2015–2020) and 0 for the pre-expansion period (2003-2009). The variable State was defined as 1 if the observation was from Kentucky (expansion state) and 0 if from Georgia (non-expansion state). The DID model is specified as: $y=X\beta+\beta_1\cdot ACA+\beta_2\cdot State + \beta_{12}\cdot (ACA \times State) + u$ [23] y represents the breast cancer outcome of interest (e.g., survival, overall mortality, or disease stage at presentation). X includes covariates such as age, race, marital status, and treatment modalities. β_1 captures the difference in outcomes between the pre- and post-ACA periods across both states. β₂ captures the baseline difference between Louisiana and Georgia. β_{12} represents the effect of Medicaid expansion on breast cancer outcomes. The interaction term ACA \times State (i.e., β_{12}) estimates the difference in the change in outcomes between Louisiana (the expansion state) and Georgia (the non-expansion state) from the pre-to the post-ACA period. This term provides the key estimate of the impact of Medicaid expansion. **Statistical Analysis** Descriptive statistics summarized the characteristics of the study population. Chi-square tests were used for categorical variables, and appropriate regression models, such as the Cox proportional hazards model, were applied to time-to-event data. Margins plots were generated to

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

visualize the adjusted probabilities of each outcome across states and time periods. Subsequently, the "lincom" command was used to calculate the DID and generate the standard error, p-value, and confidence intervals. Statistical significance was determined using two-tailed tests with an alpha level of 0.05. All analyses were conducted using STATA 16 statistical software. **RESULT Baseline Study Characteristics** In Table 1, the baseline characteristics of individuals with prostate cancer in Georgia and Kentucky were compared across two time periods, pre-ACA (2003-2009) and post-ACA (2015-2021). In the pre-ACA period, the mean age of diagnosis was similar between the two states, with Georgia at 57.3 ± 5.2 years and Kentucky at 57.6 ± 5.0 years. Post-ACA, the mean age slightly increased in both states, with Georgia at 58.1 ± 4.8 years and Kentucky at 58.4 ± 4.7 years. In terms of race and ethnicity, Georgia had a significantly higher proportion of Non-Hispanic Black people compared to Kentucky in both periods. Pre-ACA, 37.0% of patients in Georgia were Non-Hispanic Black people, compared to only 10.5% in Kentucky. Post-ACA, the proportion of Non-Hispanic Black people in Georgia further increased to 47.7%, while in Kentucky, it remained relatively low at 14.2%. In terms of tumor stage at diagnosis, the proportion of localized cases decreased significantly in both states post-ACA. In Georgia, localized cases dropped from 85.8% pre-ACA to 77.2% post-ACA, while in Kentucky, they decreased from 80.5% to 68.5%. Additionally, the incidence of distant-stage prostate cancer increased in both states post-ACA, rising from 2.7% to 5.2% in Georgia and from 2.8% to 4.6% in Kentucky. Metropolitan status also revealed significant

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

differences, with a higher proportion of patients in Kentucky residing in rural areas compared to Georgia during both periods. For example, in the post-ACA period, 23.0% of patients in Kentucky lived in rural areas not adjacent to metropolitan areas, compared to only 4.2% in Georgia. **Factor associated with CSS** Table 2 reveals factors associated with CSS among individuals with prostate cancer; comparing Georgia and Kentucky across pre-ACA and post-ACA periods. The post-2015 period was associated with improved survival outcomes, with a hazard ratio (HR) of 0.78 (95% CI: 0.68– 0.89), indicating a significant reduction in the risk of cancer-specific mortality. Additionally, the interaction between states and the post-Medicaid expansion period revealed that individuals in Kentucky had a substantial reduction in mortality post-expansion period (HR = 0.71, 95% CI: 0.56–0.90), suggesting a beneficial effect of the policy in reducing cancer-specific mortality in this state. Other covariates also played a critical role in the CSS. Older age (45-64yrs) was associated with increased mortality (HR = 1.44, 95% CI: 1.00–2.07), while being married was protective (HR = 0.65, 95% CI: 0.58–0.74). Racial disparities were evident, with Non-Hispanic Black people having a higher risk of mortality (HR = 1.10, 95% CI: 1.00–1.22) compared to Non-Hispanic White people. Socioeconomic factors, such as living in large metropolitan areas, were associated with improved survival (HR = 0.74, 95% CI: 0.63–0.87). Advanced cancer stages were strongly associated with worse outcomes, with stage IV having the highest mortality risk (HR = 26.99, 95% CI: 11.85–61.46). Additionally, treatment factors such as receiving a prostatectomy significantly reduced the risk of mortality (HR = 0.38, 95% CI: 0.33–0.43), while chemotherapy

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

Predicted Probabilities (CSS)

and radiation were associated with increased mortality risk (HR = 1.62, 95% CI: 1.39–1.89; HR = 1.20, 95% CI: 1.09–1.33, respectively). Factors associated with Overall survival In table 3, it reports the factors associated with the overall survival among individuals with prostate cancers in both states and in both time periods. The post-2015 period was associated with improved overall survival, with a hazard ratio (HR) of 0.90 (95% CI: 0.82–0.99), indicating a significant reduction in the risk of overall mortality during the period. The interaction between state and post-Medicaid expansion period showed that individuals in Kentucky had a reduction in mortality post-ACA (HR = 0.87, 95% CI: 0.75–1.01), although this effect was marginally significant (p = 0.065). Other covariates also played a crucial role in overall survival. Age between 45-64yrs. was significantly associated with higher mortality (HR = 2.17, 95% CI: 1.69–2.81), while being married was also protective (HR = 0.65, 95% CI: 0.61–0.70). Racial disparities were evident, with Non-Hispanic Black people having a higher risk of mortality (HR = 1.10, 95% CI: 1.04– 1.17) compared to Non-Hispanic White people. Socioeconomic factors, such as living in large metropolitan areas, were associated with improved survival (HR = 0.71, 95% CI: 0.65–0.78). Advanced cancer stages were strongly associated with worse outcomes, with stage IV having the highest mortality risk (HR = 4.05, 95% CI: 2.99–5.48). Additionally, treatment factors such as receiving a prostatectomy significantly reduced the risk of mortality (HR = 0.47, 95% CI: 0.44– 0.51), while chemotherapy was associated with increased mortality risk (HR = 1.42, 95% CI: 1.24–1.62).

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

Table 4 reveals the predicted probabilities of the hazards of death for CSS between Georgia and Kentucky in the pre-ACA and post-ACA across different races/ethnicities and in the overall populations. In both states and across all races and ethnicities, the post-2015 period was associated with an improvement in CSS. Specifically, for the overall population, the probability of death decreased from 5.41 (95% CI: 1.55-9.28) in the pre-ACA period to 4.22 (95% CI: 1.10-7.35) in the post-ACA period in Georgia and from 6.02 (95% CI: 1.63-10.41) to 3.34 (95% CI: 0.80-5.88) in Kentucky. Among Non-Hispanic White people, the probabilities followed a similar trend, with the post-ACA period showing reduced risks compared to the pre-ACA period, such as in Kentucky, where the probability decreased from 5.79 (95% CI: 1.58-10.00) to 3.21 (95% CI: 0.78-5.65). Non-Hispanic Black people also experienced a reduction in the predicted probabilities of death post-ACA, with a decrease from 6.39 (95% CI: 1.69-11.09) to 3.54 (95% CI: 0.82-6.27) in Kentucky. Hispanic people, Non-Hispanic Asian/Pacific Islander people, and Native American people also showed a reduction in the post-ACA period across both states. **Predicted Probabilities (Overall Survival)** Table 5 shows the predicted probabilities of overall survival between Georgia and Kentucky in the pre-ACA and post-ACA periods across racial and ethnic groups. In the overall population, the post-2015 period in Georgia experienced a reduction in the probability of death from 1.06 (95% CI: 0.81-1.31) pre-ACA to 0.95 (95% CI: 0.70-1.21) post-ACA. Similarly, in Kentucky, the probability of death decreased from 1.25 (95% CI: 0.94-1.56) pre-ACA to 0.98 (95% CI: 0.70-1.26) post-ACA. Among Non-Hispanic White people, a similar trend was observed, with the pre-ACA probability decreasing from 1.02 (95% CI: 0.78-1.26) to 0.92 (95% CI: 0.67-1.17) in Georgia and from 1.21 (95% CI: 0.91-1.51) to 0.94 (95% CI: 0.67-1.22) in Kentucky.

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

For Non-Hispanic Black people, the predicted probability of death post-ACA decreased from 1.13 (95% CI: 0.86-1.40) to 1.02 (95% CI: 0.74-1.29) in Georgia and from 1.33 (95% CI: 0.99-1.67) to 1.04 (95% CI: 0.73-1.35) in Kentucky. Hispanic people also experienced a decrease in the probability of death, particularly in Kentucky, where the post-ACA period saw a reduction from 1.00 (95% CI: 0.69-1.32) to 0.91 (95% CI: 0.60-1.21). This pattern was also seen among Non-Hispanic Asian/Pacific Islander people and Native Americans people. **DID for Cancer-Specific Survival** Table 6 reports the DID output on the change in the hazard of death for CSS among individuals with prostate cancer. Overall, the coefficient for all individuals was -1.49 (95% CI: -3.00 to 0.02, p=0.053), indicating a marginally significant reduction in the hazard of death. When broken down by race/ethnicity, Non-Hispanic White people showed a similar reduction (Coef. = -1.44, 95% CI: -2.89 to 0.01, p=0.052), as did Non-Hispanic Black people (Coef. = -1.58, 95% CI: -3.19 to 0.02, p=0.054), both nearing statistical significances. Hispanic people also experienced a reduction in hazard (Coef. = -1.24, 95% CI: -2.55 to 0.08, p=0.065), though the result was slightly less significant. The reduction was more pronounced for NHAPI people (Coef. = -1.76, 95% CI: -3.84 to 0.31, p=0.096), though it did not reach statistical significance. Native Americans showed the least reduction in hazard, with a coefficient of -0.67 (95% CI: -2.14 to 0.81, p=0.376), indicating no significant change. **DID for Overall Cancer Survival** Table 7 reveals the DID results on the change in the hazard of death for overall survival among individuals with prostate cancers. There was a substantive reduction in mortality risk across most racial and ethnic groups post-Medicaid expansion in Kentucky compared to Georgia. For the overall population, the analysis showed a modest but statistically significant decrease in the

hazard of death, with a coefficient of -0.17 (95% CI: -0.33 to -0.01, p=0.039). This trend was consistent across Non-Hispanic White people (Coef. = -0.16, 95% CI: -0.32 to -0.01, p=0.039) and Non-Hispanic Black people (Coef. = -0.18, 95% CI: -0.35 to -0.01, p=0.039) people, both of which experienced significant reductions in mortality risk. Hispanic people also experienced a significant reduction in hazard (Coef. = -0.16, 95% CI: -0.31 to -0.01, p=0.043). Non-Hispanic Asian/Pacific Islander people showed a similar, though marginally significant, reduction (Coef. = -0.12, 95% CI: -0.24 to 0.00, p=0.060). Native Americans had the smallest reduction, with a coefficient of -0.07 (95% CI: -0.19 to 0.05, p=0.245), indicating no significant change in overall survival.

DISCUSSION

Overall, there was a decline in the predicted probabilities of cancer-specific deaths in the post2015 period, observed across both states regardless of Medicaid expansion status. However, this
trend was not mirrored in the risk of overall deaths, as no significant difference was noted
between the pre- and post-Medicaid expansion periods for overall survival in either state. While
a more pronounced reduction in cancer-specific mortality was noted in Kentucky compared to
Georgia, the difference was not statistically significant. Conversely, there was a significant 16.8
percentage point decrease in overall mortality risk among individuals with prostate cancer in
Kentucky relative to Georgia, with the reduction ranging from -32.6% to -9%. This improvement
in overall survival was consistent across different racial/ethnic groups and was particularly
notable among Black individuals, who experienced a 17.9 percentage point drop in the risk of
overall deaths compared to their counterparts in Georgia. Other significant predictors of
improved cancer-specific and overall survival included younger age, White race, higher
household median income, married status, and residence in metropolitan areas. Undergoing

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

prostatectomy was significantly associated with improved survival, while radiation therapy did not show a significant effect. In contrast, chemotherapy was linked to worse cancer-specific and overall survival, potentially due to higher disease burden among individuals receiving this treatment modality. The improvement in survival among individuals diagnosed with prostate cancer in recent years is likely multifactorial. Advances in early detection and screening methods, particularly widespread adoption of prostate-specific antigen (PSA) testing, have facilitated diagnosis at earlier, more treatable stages. Additionally, innovations in treatment modalities—including the development of more effective surgical techniques, radiotherapy, androgen deprivation therapy, and novel targeted therapies—have significantly enhanced disease management. Increased access to multidisciplinary care, improved supportive therapies, and heightened awareness of prostate cancer through public health campaigns have also contributed to better outcomes. Furthermore, there has been an overall improvement in healthcare delivery systems and a greater emphasis on personalized treatment approaches tailored to patients' genetic and molecular profiles, which may account for the observed survival gains. When comparing the change in prostate cancer-specific mortality between Kentucky and Georgia, there were no statistically significant differences, although the results indicated a trend towards a greater decline in Kentucky. This suggests that while there may be a modest reduction in prostate cancer-specific deaths following the implementation of the ACA and Medicaid expansion in Kentucky, the findings do not provide robust evidence of a substantive improvement in outcomes relative to Georgia. The absence of a substantive impact of Medicaid expansion on prostate cancer outcomes in Kentucky compared to Georgia may be attributed to several factors. Prostate cancer is generally

338

339

340

341

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

357

358

359

a slow-growing malignancy with a favorable prognosis, and the benefits of improved healthcare access may take years to manifest in survival outcomes. The indolent nature of the disease, coupled with high baseline survival rates, could dilute the measurable effects of policy changes within the study timeframe. Moreover, while we observed a trend towards a greater decline in prostate cancer-specific mortality in Kentucky, the lack of statistical significance suggests that the improvement may be influenced by other concurrent healthcare advancements or socioeconomic factors not directly related to Medicaid expansion. These nuances indicate that longer follow-up periods or studies focusing on more aggressive cancers might be needed to detect the full impact of Medicaid expansion on cancer-specific outcomes. Kentucky, a Medicaid expansion state, demonstrated a significant 16.8% reduction in overall mortality risk compared to Georgia, a non-expansion state. This is particularly notable because overall mortality, unlike cancer-specific mortality, may more comprehensively capture the broader benefits of Medicaid expansion, such as improved access to preventive care, management of comorbidities, and timely interventions for acute conditions. Given the generally indolent nature of prostate cancer, the impact of Medicaid expansion on prostate cancer-specific deaths may take longer to manifest, whereas the significant reduction in all-cause mortality in Kentucky suggests that enhanced healthcare access had an immediate and measurable effect on broader health outcomes. This finding is important in light of the fact that no statistically significant change in overall mortality was observed across the study period in either state, emphasizing that the mortality reduction in Kentucky may be directly attributable to increased healthcare access following the implementation of the ACA and its Medicaid expansion component. These results highlight the potential of Medicaid expansion to reduce health disparities and improve survival, particularly in

361

362

363

364

365

366

367

368

369

370

371

372

373

374

375

376

377

378

379

380

381

382

populations that were previously uninsured or underinsured, reinforcing the role of policy-driven healthcare reforms in enhancing population health outcomes. Interestingly, individuals who received chemotherapy experienced a significantly higher hazard of both cancer-specific and overall mortality. This may be explained by a higher disease burden and more advanced cancer stage at the time of treatment, as chemotherapy is often reserved for high-risk or metastatic cases. Additionally, the observed mortality risk may reflect an imbalance in sociodemographic and clinical factors, as patients receiving chemotherapy were more likely to belong to vulnerable groups such as low-income families, unmarried or single individuals, and racial minorities—populations that often have limited access to comprehensive healthcare and may present with more aggressive disease. Moreover, disparities in treatment adherence and supportive care in these groups could further contribute to poorer outcomes, underscoring the need for tailored interventions to address these inequities and improve survival among chemotherapy-treated patients. This study highlights persistent disparities in cancer outcomes, with Black individuals, those from the lowest-income households, single and unmarried individuals, and residents of rural areas facing the highest risk of both cancer-specific and overall mortality. These disparities may be driven by a combination of factors, including delayed diagnosis, limited access to high-quality care, and a greater burden of comorbidities in these populations. Additionally, socioeconomic barriers and geographical challenges often result in reduced access to advanced treatments and follow-up care, further exacerbating survival disparities. STRENGHT AND LIMITATIONS. This study has several strengths, including the use of the SEER registry, a high-quality, population-based cancer database that provides comprehensive clinical and demographic

384

385

386

387

388

389

390

391

392

393

394

395

396

397

398

399

400

401

402

403

404

405

information, allowing for robust analysis of cancer outcomes. A key strength is our approach of comparing two states with similar demographic profiles—Kentucky and Georgia—rather than grouping states broadly into Medicaid expansion versus non-expansion categories. This approach mitigates the potential bias introduced by heterogeneity in Medicaid implementation timelines and healthcare infrastructure across states, enhancing the specificity of our findings. Furthermore, the use of a DID approach allows for stronger causal inferences from observational data by accounting for underlying time trends, thus providing a more accurate estimate of the impact of Medicaid expansion on survival outcomes. However, our study has limitations, including the inability to control pre-existing comorbidities or baseline insurance status, which may influence both treatment decisions and survival outcomes. Additionally, unmeasured factors such as differences in healthcare delivery systems, patient adherence, and provider practices could also affect mortality and potentially confound our results. Despite these limitations, our study offers valuable insights into the nuanced effects of Medicaid expansion on cancer outcomes and overall mortality. In conclusion, while we did not observe a significant difference in prostate cancer-specific mortality or survival between Kentucky and Georgia, Kentucky's Medicaid expansion was associated with a notable improvement in overall survival, evidenced by a significant reduction in all-cause mortality compared to Georgia. This finding underscores the broader impact of Medicaid expansion on health outcomes beyond cancer-specific measures, highlighting the policy's potential to reduce overall mortality through improved healthcare access. However, significant disparities persist, with Black individuals, low-income households, rural residents, and unmarried individuals continuing to experience poorer outcomes in both cancer-specific and overall survival. These results emphasize the need for targeted strategies to address these

inequities and ensure that the benefits of expanded healthcare coverage reach the most

407 vulnerable populations.

REFERENCE

408

409

412

415

418 419

420

421

422 423

424

425

428

432

435

437

- CDC NBaCEDP. Prostate Cancer Statistics 2024 [Available from:
 https://www.cdc.gov/prostate-cancer/statistics/index.html.
- 2. American Cancer Society. Key Statistics for Prostate Cancer 2024 [Available from: https://www.cancer.org/cancer/types/prostate-cancer/about/key-statistics.html.
- 3. NIH NCI. Prostate Cancer Treatment (PDQ®)—Patient Version 2023 [Available from: https://www.cancer.gov/types/prostate/patient/prostate-treatment-pdq.
 - 4. Showalter TN, Mishra MV, Bridges JF. Factors that influence patient preferences for prostate cancer management options: A systematic review. Patient Prefer Adherence. 2015;9:899-911.
 - 5. Imber BS, Varghese M, Ehdaie B, Gorovets D. Financial toxicity associated with treatment of localized prostate cancer. Nat Rev Urol. 2020;17(1):28-40.
- NIH NCI. Financial Burden of Cancer Care 2024 [Available from:
 https://progressreport.cancer.gov/after/economic_burden.
- Islami F, Miller KD, Siegel RL, Zheng Z, Zhao J, Han X, et al. National and State
 Estimates of Lost Earnings From Cancer Deaths in the United States. JAMA Oncology.
 2019;5(9):e191460-e.
- 8. Schrecengost R, Knudsen KE. Molecular pathogenesis and progression of prostate cancer.
 Semin Oncol. 2013;40(3):244-58.
- 9. Gann PH. Risk factors for prostate cancer. Rev Urol. 2002;4 Suppl 5(Suppl 5):S3-s10.
- 10. Coughlin SS. A review of social determinants of prostate cancer risk, stage, and survival.
 Prostate Int. 2020;8(2):49-54.

11. Vince RA, Jr., Jiang R, Bank M, Quarles J, Patel M, Sun Y, et al. Evaluation of Social
 Determinants of Health and Prostate Cancer Outcomes Among Black and White Patients:
 A Systematic Review and Meta-analysis. JAMA Netw Open. 2023;6(1):e2250416.

- 12. Vince RA, Jr, Jiang R, Bank M, Quarles J, Patel M, Sun Y, et al. Evaluation of Social
 Determinants of Health and Prostate Cancer Outcomes Among Black and White Patients:
 A Systematic Review and Meta-analysis. JAMA Network Open. 2023;6(1):e2250416-e.
 - 13. National Archives MD. Medicare and Medicaid Act (1965) 2022 [Available from: https://www.archives.gov/milestone-documents/medicare-and-medicaid-act.
 - 14. Lyon SM, Douglas IS, Cooke CR. Medicaid expansion under the Affordable Care Act. Implications for insurance-related disparities in pulmonary, critical care, and sleep. Ann Am Thorac Soc. 2014;11(4):661-7.
 - 15. Cohen WJ. Reflections on the enactment of Medicare and Medicaid. Health Care Financ Rev. 1985;Suppl(Suppl):3-11.
- 459 16. Kominski GF, Nonzee NJ, Sorensen A. The Affordable Care Act's Impacts on Access to
 460 Insurance and Health Care for Low-Income Populations. Annu Rev Public Health.
 461 2017;38:489-505.
 - 17. Takvorian SU, Oganisian A, Mamtani R, Mitra N, Shulman LN, Bekelman JE, et al. Association of Medicaid Expansion Under the Affordable Care Act With Insurance Status, Cancer Stage, and Timely Treatment Among Patients With Breast, Colon, and Lung Cancer. JAMA Network Open. 2020;3(2):e1921653-e.
 - 18. Eguia E, Cobb AN, Kothari AN, Molefe A, Afshar M, Aranha GV, et al. Impact of the Affordable Care Act (ACA) Medicaid Expansion on Cancer Admissions and Surgeries. Ann Surg. 2018;268(4):584-90.
- 19. NIH NCI. SEER Databases in SEER*Stat [Available from: https://seer.cancer.gov/data-software/documentation/seerstat/.
- 20. NIH NCI. Overview of the SEER Program [Available from:
 https://seer.cancer.gov/about/overview.html.
- 478 21. Alkhawaldeh A, M AL, Rayan A, Abdalrahim A, Musa A, Eshah N, et al. Application and
 479 Use of Andersen's Behavioral Model as Theoretical Framework: A Systematic Literature
 480 Review from 2012-2021. Iran J Public Health. 2023;52(7):1346-54.

482 22. Krzyż EZ, Antunez Martinez OF, Lin HR. Uses of Andersen health services utilization
 483 framework to determine healthcare utilization for mental health among migrants-a scoping
 484 review. Front Public Health. 2023;11:1284784.

- 23. Forcasting SMa. Introduction To The Difference-In-Differences Regression Model [Available from: https://timeseriesreasoning.com/contents/introduction-to-the-difference-in-differences-regression-model
- 24. Janopaul-Naylor JR, Corriher TJ, Switchenko J, Hanasoge S, Esdaille A, Mahal BA, et al. Disparities in time to prostate cancer treatment initiation before and after the Affordable Care Act. Cancer Med. 2023;12(17):18258-68.
 - 25. Bhatia S, Landier W, Paskett ED, Peters KB, Merrill JK, Phillips J, et al. Rural-Urban Disparities in Cancer Outcomes: Opportunities for Future Research. J Natl Cancer Inst. 2022;114(7):940-52.
 - 26. Miao Q, Wei Z, Liu C, Ye Y, Cheng G, Song Z, et al. Overall survival and cancer-specific survival were improved in local treatment of metastatic prostate cancer. Frontiers in Oncology. 2023;13.
 - 27. Liu W, Goodman M, Filson CP. Association of State-Level Medicaid Expansion With Treatment of Patients With Higher-Risk Prostate Cancer. JAMA Network Open. 2020;3(10):e2015198-e.
 - 28. Lowder D, Rizwan K, McColl C, Paparella A, Ittmann M, Mitsiades N, et al. Racial disparities in prostate cancer: A complex interplay between socioeconomic inequities and genomics. Cancer Lett. 2022;531:71-82.
 - 29. Zeng H, Xu M, Xie Y, Nawrocki S, Morze J, Ran X, et al. Racial/ethnic disparities in the cause of death among patients with prostate cancer in the United States from 1995 to 2019: a population-based retrospective cohort study. eClinicalMedicine. 2023;62.
- 30. Krajc K, Miroševič Š, Sajovic J, Klemenc Ketiš Z, Spiegel D, Drevenšek G, et al. Marital status and survival in cancer patients: A systematic review and meta-analysis. Cancer Med. 2023;12(2):1685-708.
 - 31. Lewis-Thames MW, Langston ME, Khan S, Han Y, Fuzzell L, Xu S, et al. Racial and Ethnic Differences in Rural-Urban Trends in 5-Year Survival of Patients With Lung,

- Prostate, Breast, and Colorectal Cancers: 1975-2011 Surveillance, Epidemiology, and End Results (SEER). JAMA Network Open. 2022;5(5):e2212246-e.
- 32. Maganty A, Byrnes ME, Hamm M, Wasilko R, Sabik LM, Davies BJ, et al. Barriers to
 rural health care from the provider perspective. Rural Remote Health. 2023;23(2):7769.

- 33. Afshar N, English DR, Milne RL. Factors Explaining Socio-Economic Inequalities in Cancer Survival: A Systematic Review. Cancer Control. 2021;28:10732748211011956.
 - 34. Cella DF, Orav EJ, Kornblith AB, Holland JC, Silberfarb PM, Lee KW, et al. Socioeconomic status and cancer survival. J Clin Oncol. 1991;9(8):1500-9.
- 35. Courtemanche C, Marton J, Ukert B, Yelowitz A, Zapata D, Fazlul I. The three-year impact of the Affordable Care Act on disparities in insurance coverage. Health Serv Res. 2019;54 Suppl 1(Suppl 1):307-16.
- 36. Aljassim N, Ostini R. Health literacy in rural and urban populations: A systematic review.
 Patient Educ Couns. 2020;103(10):2142-54.
- 37. Unger JM, Moseley A, Symington B, Chavez-MacGregor M, Ramsey SD, Hershman DL.
 Geographic Distribution and Survival Outcomes for Rural Patients With Cancer Treated in
 Clinical Trials. JAMA Network Open. 2018;1(4):e181235-e.
 - 38. Forjaz G, Ries L, Devasia TP, Flynn G, Ruhl J, Mariotto AB. Long-term Cancer Survival Trends by Updated Summary Stage. Cancer Epidemiol Biomarkers Prev. 2023;32(11):1508-17.
 - 39. Benitez JA, Creel L, Jennings J. Kentucky's Medicaid Expansion Showing Early Promise On Coverage And Access To Care. Health Aff (Millwood). 2016;35(3):528-34.
 - 40. Martinez ME, Gomez SL, Canchola AJ, Oh DL, Murphy JD, Mehtsun W, et al. Changes in Cancer Mortality by Race and Ethnicity Following the Implementation of the Affordable Care Act in California. Front Oncol. 2022;12:916167.
- 41. Hotca A, Bloom JR, Runnels J, Salgado LR, Cherry DR, Hsieh K, et al. The Impact of
 Medicaid Expansion on Patients with Cancer in the United States: A Review. Curr Oncol.
 2023;30(7):6362-73.

42. Akinyemi OA, Weldeslase TA, Fasokun ME, Odusanya E, Mejulu EO, Salihu EY, et al. Causal Effects of the Affordable Care Act (ACA) Implementation on Non-Hodgkin's Lymphoma Survival: A Difference-in-Differences Analysis. Cureus. 2024;16(1):e52571.

43. Enyeji AM, Barengo NC, Ramirez G, Ibrahimou B, Arrieta A. Regional Variation in Health Care Utilization Among Adults With Inadequate Cardiovascular Health in the USA. Cureus. 2023;15(8):e44121.

Table 1: Demographic, Clinical, and Treatment Characteristics of Individuals with Prostate Cancer in Georgia and Kentucky Before and After Medicaid Expansion in Kentucky in 2014.

Variables		ACA (2003-2009) (N=37,810)		Post-	ACA (2015-2021) (N=30,412)	
variables	Georgia (N=26,772)	Kentucky (N=11,038)	P-value	Georgia (N=48,910)	Kentucky (N=19,312)	P-value
Age (years; Mean \pm SD)	57.3 ± 5.2	57.6± 5.0	< 0.01	58.1 ± 4.8	58.4 ± 4.7	< 0.01
Age						
18-44yrs.	567 (2.1%)	163 (1.5%)	< 0.01	251 (1.1%)	72 (0.9%)	0.046
45-64yrs.	26,205 (97.9%)	10,875 (98.5%)		21,887 (98.9%)	8,202 (99.1%)	
Race/Ethnicity			< 0.01			< 0.01
White Person	16,158 (60.4%)	9,698 (87.9%)		10,366 (46.8%)	6,679 (80.7%)	
Black Person	9,895 (37.0%)	1,163 (10.5%)		10,566 (47.7%)	1,171 (14.2%)	
Hispanic Person	453 (1.7%)	57 (0.5%)		740 (3.3%)	80 (1.0%)	
Other	266 (1.0%)	120 (1.1%)		466 (2.1%)	344 (4.2%)	
Income			< 0.001			< 0.001
<65K	12,679 (47.4%)	9,432 (85.5%)		9,739 (44.0%)	7,008 (84.7%)	
≥65K	14,093 (52.6%)	1,606 (14.6%)		12,399 (56.0%)	1,266 (15.3%)	
Marital Status			< 0.001			< 0.01
Single	2,944 (11.0%)	754 (6.8%)		3,465 (15.7%)	968 (11.8%)	
Married	18,772 (70.1%)	7,358 (66.7%)		12,862 (58.3%)	4,883 (59.3%)	
Widowed	507 (1.9%)	196 (1.8%)		331 (1.5%)	162 (2.0%)	
Divorced	2,277 (8.5%)	997 (9.0%)		1,566 (7.1%)	845 (10.3%)	
Separated	273 (1.0%)	56 (0.5%)		197 (0.9%)	46 (0.6%)	
Unknown	1,988 (7.5%)	1,677 (15.2%)		3,649 (16.5%)	1,334 (16.2%)	
Metropolitan Status			< 0.001			< 0.001
Rural areas not adjacent to metropolitan areas	1,081 (4.0%)	2,464 (22.3%)		930 (4.2%)	1,900 (23.0%)	
Rural areas adjacent to metropolitan areas	3,648 (13.6%)	1,809 (16.4%)		2,437 (11.0%)	1,273 (15.4%)	
Small metropolitan areas	4,037 (15.1%)	925 (8.4%)		3,020 (13.6%)	793 (9.6%)	

Medium metropolitan areas	3,005 (11.2%)	1,704 (15.4%)		2,459 (11.1%)	1,262 (15.3%)	
Large metropolitan areas	15,001 (56.0%)	4,136 (37.5%)		13,292 (60.0%)	3,046 (36.8%)	
Stage at presentation			< 0.01			< 0.01
Localized	15,383 (85.8%)	5,731 (80.5%)		6,855 (77.2%)	2,395 (68.5%)	
Regional	1,802 (10.1%)	1,081 (15.2%0		1,237 (13.9%)	557 (15.9%)	
Distant	480 (2.7%)	196 (2.8%)		463 (5.2%)	160 (4.6%)	
Unknown	271 (1.5%)	109 (1.5%)		328 (3.7%)	384 (11.0%)	
Surgery, n (%)			< 0.001			< 0.01
Yes	14,217 (54.0%)	3,635 (35.7%)		13,867 (63.0%)	4,088 (54.8%)	
None/Unknown	12,135 (46.1%)	6,551 (64.3%)		8,143 (37.0%)	3,369 (45.2%)	
Chemotherapy, n (%)			0.345			0.106
Yes	191 (0.7%)	69 (0.6%)		445 (2.0%)	191 (2.3%)	
None/Unknown	26,581 (99.2%)	10,969 (99.4%)		21,693 (98.0%)	8,083 (97.7%)	
Radiotherapy, n (%)			< 0.01			< 0.01
Yes	7,994 (34.2%)	1,908 (19.5%)		5,210 (25.5%)	2,197 (27.6%)	
None/Unknown	15,390 (65.8%)	7,898 (80.5%)		15,242 (74.5%)	5,766 (72.4%)	

Table 2: Cox Proportional Hazards Model Assessing Factors Associated with Cancer-Specific Survival among Individuals with Prostate Cancer.

Variables	Haz. Ratio	Std. Err.	z	P>z	[95% Con	f. Interval]
State						
Kentucky (ref. Georgia)	1.181	0.039	5.050	0.000	1.107	1.259
ACA						
Post-ACA (ref. Pre-ACA)	0.901	0.042	-2.260	0.024	0.823	0.986
State x ACA						
Kentucky x Post-ACA	0.868	0.067	-1.850	0.065	0.747	1.009
Age						
18-44yrs.	Reference					
45-64yrs.	2.175	0.283	5.980	0.000	1.686	2.806
Race/Ethnicity						
White Person	Reference					
Black Person	1.103	0.031	3.480	0.001	1.044	1.166
Hispanics	0.983	0.103	-0.170	0.867	0.801	1.206
Other	0.741	0.162	-1.370	0.171	0.482	1.139
Household Median Income						
Income \geq 64K (ref. \leq 64K)	0.878	0.030	-3.840	0.000	0.822	0.938
Marital Status						
Single	Reference					
Married	0.649	0.023	-11.960	0.000	0.605	0.697

	T					
Widowed	1.126	0.091	1.470	0.141	0.961	1.319
Divorced	0.994	0.046	-0.130	0.895	0.908	1.088
Separated	1.060	0.112	0.550	0.581	0.861	1.305
Unknown	0.751	0.040	-5.430	0.000	0.678	0.833
Metropolitan Status						
Rural areas not adjacent to metropolitans	Reference					
Rural areas adjacent to metropolitans	0.964	0.045	-0.770	0.441	0.880	1.058
Small metropolitan areas	0.819	0.041	-3.990	0.000	0.743	0.904
Medium metropolitan areas	0.776	0.039	-5.060	0.000	0.703	0.856
Large metropolitan areas	0.713	0.033	-7.340	0.000	0.652	0.781
Grade						
Localized	Reference					
Regional	1.133	0.099	1.430	0.154	0.954	1.345
Distant	3.482	0.387	11.230	0.000	2.801	4.329
Stage at Presentation						
Stage I	Reference					
Stage II	1.449	0.168	3.200	0.001	1.155	1.819
Stage III	2.135	0.318	5.100	0.000	1.595	2.858
Stage IV	4.047	0.625	9.060	0.000	2.991	5.477
Prostatectomy	0.473	0.017	-21.050	0.000	0.441	0.507
Chemotherapy	1.421	0.097	5.130	0.000	1.243	1.625
Radiation	1.017	0.032	0.530	0.598	0.956	1.082

Table 3: Cox Proportional Hazards Model Assessing Factors Associated with Overall Survival among Individuals with Prostate Cancer.

Variables	Haz. Ratio	Std. Err.	z	P>z	[95% Con	f. Interval]
State						
Kentucky (ref. Georgia)	1.112	0.068	1.750	0.080	0.987	1.253
ACA						
Post-ACA (ref. Pre-ACA)	0.780	0.054	-3.610	0.000	0.682	0.893
State x ACA						
Kentucky x Post-ACA	0.711	0.087	-2.770	0.006	0.559	0.905
Age						
18-44yrs.	Reference					
45-64yrs.	1.440	0.266	1.980	0.048	1.003	2.068
Race/Ethnicity						
White	Reference					
Black	1.103	0.055	1.970	0.049	1.000	1.215

Hispanics	0.862	0.154	-0.830	0.406	0.608	1.223
Other	1.229	0.374	0.680	0.499	0.676	2.233
Household Median Income	1.22)	0.571	0.000	0.155	0.070	2.233
Income \geq 64K (ref. $<$ 64K)	0.935	0.055	-1.140	0.253	0.832	1.049
Marital Status	0.555	0.022	1.110	0.200	0.032	1.015
Single	Reference					
Married	0.653	0.040	-6.980	0.000	0.580	0.736
Widowed	1.065	0.148	0.450	0.652	0.810	1.399
Divorced	0.834	0.066	-2.310	0.021	0.714	0.973
Separated	0.835	0.154	-0.980	0.330	0.581	1.200
Unknown	0.863	0.078	-1.630	0.102	0.723	1.030
Metropolitan Status						
Rural areas not adjacent to metropolitan areas	Reference					
Rural areas adjacent to metropolitan areas	0.915	0.077	-1.050	0.294	0.775	1.080
Small metropolitan areas	0.752	0.068	-3.140	0.002	0.629	0.898
Medium metropolitan areas	0.816	0.073	-2.270	0.023	0.684	0.973
Large metropolitan areas	0.738	0.062	-3.630	0.000	0.626	0.870
Grade						
Localized	Reference					
Regional	1.269	0.268	1.130	0.258	0.839	1.919
Distant	4.357	0.981	6.540	0.000	2.803	6.773
Stage at Presentation						
Stage I	Reference					
Stage II	3.203	1.152	3.240	0.001	1.583	6.482
Stage III	10.432	4.363	5.610	0.000	4.596	23.677
Stage IV	26.988	11.333	7.850	0.000	11.851	61.461
Prostatectomy	0.378	0.025	-14.840	0.000	0.332	0.430
Chemotherapy	1.622	0.127	6.180	0.000	1.391	1.891
Radiation	1.204	0.060	3.740	0.000	1.092	1.327

Table 4: Predicted Probabilities of Cancer-Specific Survival Among Individuals Prostate Cancer

Variables	ALL	White	Black	Hispanic	NHAPI	Native Americans
Georgia x	5.41 (1.55-	5.21 (1.49-	5.74 (1.61-	4.49 (0.94-	6.40 (0.44-	
Post-ACA	9.28)	8.93)	9.88)	8.04)	12.36)	2.42 (-2.63-7.47)
Georgia x	4.22 (1.10-	4.07 (1.06-	4.48 (1.15-	3.51 (0.67-	5.00 (0.25-	
Pre-ACA	7.35)	7.07)	7.82)	6.35)	9.75)	1.89 (-2.06-5.84)
Kentucky						
x Post-	6.02 (1.63-	5.79 (1.58-	6.39 (1.69-	5.00 (0.98-	7.12 (0.41-	
ACA	10.41)	10.00)	11.09)	9.01)	13.83)	2.69 (-2.94-9.32)

Kentucky						
x Pre-	3.34 (0.80-	3.21 (0.78-	3.54 (0.82-	2.77 (0.47-	3.95 (0.13-	
ACA	5.88)	5.65)	6.27)	5.08)	7.77)	1.49 (-1.64-4.63)

Table 5: Predicted Probabilities of Cancer-Specific Survival Among Individuals Prostate Cancer

Variables	ALL	White	Black	Hispanic	NHAPI	Native Americans
Georgia x Post-ACA	1.06 (0.81-1.31)	1.02 (0.78-1.26)	1.13 (0.86-1.40)	1.00 (0.69-1.32)	0.76 (0.39-1.13)	0.45 (-0.18-1.07)
Georgia x Pre-ACA	0.95 (0.70-1.21)	0.92 (0.67-1.17)	1.02 (0.74-1.29)	0.91 (0.60-1.21)	0.68 (0.34-1.03)	0.40 (-0.17-0.97)
Kentucky x Post-ACA	1.25 (0.94-1.56)	1.21 (0.91-1.51)	1.33 (0.99-1.67)	1.19 (0.81-1.57)	0.89 (0.45-1.34)	0.53 (-0.21-1.27)
Kentucky x Pre-ACA	0.98 (0.70-1.26)	0.94 (0.67-1.22)	1.04 (0.73-1.35)	0.93 (0.60-1.25)	0.70 (0.34-1.06)	0.41 (-0.17-0.99)

Table 6: DID Output for Cancer-Specific Survival by Race/Ethnicity

Race/Ethnicity	Std. Err.	Z	P>z	[95% Conf. Interval]	
All	-1.492	0.770	0.053	-3.000	0.017
White Person	-1.436	0.740	0.052	-2.885	0.014
Blacks Person	-1.583	0.820	0.054	-3.191	0.025
Hispanic Person	-1.238	0.671	0.065	-2.554	0.078
Asian & Pacific Islanders	-1.764	1.059	0.096	-3.839	0.311
Native Americans	-0.667	0.753	0.376	-2.142	0.808

Table 7: DID Output for Overall Survival by Race/Ethnicity

Race/Ethnicity	Coefficient	Std. Err	P>z	[95% Conf. Interval]	
All	-0.168	0.081	0.039	-0.326	-0.009
White Person	-0.162	0.078	0.039	-0.315	-0.008
Black Person	-0.179	0.086	0.039	-0.348	-0.009
Hispanic Person	-0.159	0.079	0.043	-0.313	-0.005
Asian & Pacific Islanders	-0.120	0.064	0.060	-0.245	0.005
Native Americans	-0.071	0.061	0.245	-0.190	0.048